SARMs in 2024: where the research actually stands

The Promise vs. the Reality

SARMs were supposed to be the future. The pitch was simple: all the muscle-building and bone-strengthening effects of anabolic steroids, none of the prostate enlargement, hair loss, or liver damage. Selective activation of androgen receptors in muscle and bone, without the systemic androgenic effects that make traditional steroids problematic.

That pitch was made in the early 2000s. It is now 2024, and not a single SARM has received FDA approval for any indication. Most clinical development programs have been abandoned. The compounds that do get used are purchased from gray-market vendors with no regulatory oversight.

So what happened? Let's go through the actual data.

What "Selective" Actually Means

The androgen receptor is the same protein everywhere in your body. It sits in muscle cells, bone cells, prostate cells, liver cells, brain cells, and hair follicles. Traditional anabolic steroids activate it indiscriminately in all of these tissues.

SARMs achieve "selectivity" through a different mechanism than most people assume. They do not bind to a different receptor in muscle versus prostate. Instead, they induce different conformational changes in the same androgen receptor, which leads to different co-activator recruitment patterns in different tissues.

Think of it like a key that turns a lock to different positions depending on which door it is in. The receptor's shape change in muscle tissue recruits one set of co-activator proteins; in prostate tissue, it recruits a different (ideally less active) set.

Here is the critical nuance: selectivity is relative, not absolute. Every SARM still has some activity in non-target tissues. At higher doses, that residual activity becomes clinically meaningful. The dose-response curves for anabolic effects and androgenic side effects overlap more than early marketing suggested.

The Compounds With Actual Human Data

Ostarine (MK-2866 / Enobosarm)

Ostarine has the most clinical data of any SARM. GTx Inc. (later Oncternal Therapeutics) ran it through multiple trials:

• Phase II cancer cachexia trial (2011): 159 patients randomized to placebo, 1mg, or 3mg Ostarine for 16 weeks. Both doses showed statistically significant increases in lean body mass (~1.0-1.5 kg). The 3mg group also showed improved stair climb performance.
• Phase III POWER trials (2013): Two large trials (POWER 1 and POWER 2) in cancer patients with muscle wasting. Ostarine met its lean body mass co-primary endpoint but failed the physical function co-primary endpoint (stair climb power) in both trials.
• FDA rejection: The FDA issued a Complete Response Letter. Gaining muscle mass without demonstrable functional improvement was not enough.

Key safety findings from trials: Ostarine at 3mg suppressed total testosterone by approximately 30-40% and reduced HDL cholesterol by 15-20%. At these low clinical doses. The suppression was not catastrophic, but it was real and dose-dependent.

LGD-4033 (Ligandrol / VK5211)

Ligand Pharmaceuticals developed LGD-4033, and Viking Therapeutics later picked it up as VK5211:

• Phase I (2013): 76 healthy men received placebo or 0.1, 0.3, or 1.0 mg/day for 21 days. The 1mg group gained approximately 1.21 kg lean mass. Dose-dependent suppression of total testosterone, free testosterone, and SHBG was observed. FSH and LH were also suppressed.
• Phase II for hip fracture recovery (2018): Viking Therapeutics reported positive top-line results showing increased lean body mass and improved measures of physical function in hip fracture patients. This was the most promising clinical signal for any SARM.

Key safety findings: At 1mg/day for just 21 days, total testosterone dropped by approximately 50%. HDL dropped by 40%. Both recovered after discontinuation, but the magnitude of suppression at such a low dose surprised many researchers.

RAD-140 (Testolone)

Radius Health ran a Phase I trial in postmenopausal women with breast cancer. Limited published data showed some evidence of dose-dependent safety and pharmacokinetics, but the program appears to have been deprioritized. Publicly available clinical data is minimal.

The Compounds Without Human Data

This is where things get uncomfortable for the SARM community. Several widely used SARMs have zero published human clinical trial data:

• S-4 (Andarine): Preclinical data only. Known for causing a yellow tint to vision at higher doses in users (binding to retinal androgen receptors -- so much for selectivity). GTx shelved it.
• S-23: Preclinical only. Animal data showed potent anabolic effects but also significant prostate weight increases, which defeats the entire purpose.
• YK-11: Not technically a SARM -- it is a steroidal compound that may act as a myostatin inhibitor. One cell culture study. That is it.
• MK-677 (Ibutamoren): Not a SARM at all. It is a growth hormone secretagogue (ghrelin receptor agonist). It does have human data, but it gets lumped in with SARMs constantly. A 2-year study showed increased GH and IGF-1 but also increased fasting glucose, insulin resistance, and HbA1c. Not the clean profile people assume.

The Liver Problem

Starting around 2017, case reports of SARM-associated liver injury began appearing in medical literature. By 2023, there were dozens:

• A 2020 review in ACG Case Reports Journal documented cholestatic liver injury from LGD-4033
• Multiple case reports of jaundice requiring hospitalization from RAD-140
• A 2021 Drug Safety systematic review identified liver injury as the most common serious adverse event in SARM case reports
• The pattern typically involves cholestatic hepatitis -- elevated bilirubin, alkaline phosphatase, and GGT -- appearing 4-8 weeks after starting use

Important context: Many of these cases involved products purchased online that may have been contaminated or mislabeled. A 2017 JAMA study found that only 52% of products sold as SARMs actually contained the labeled SARM. Some contained none of it. Others contained different SARMs, anabolic steroids, or unknown compounds.

This means the liver toxicity signal is real but confounded. Is it the SARM itself? A contaminant? A manufacturing impurity? With unregulated products, it is genuinely impossible to know.

Why Clinical Development Has Stalled

The pattern is consistent across almost every SARM:

1. Early-phase results look promising. Small gains in lean mass, generally tolerable side effects.
2. Suppression turns out to be real. Every SARM with human data shows dose-dependent testosterone suppression. The selectivity is not clean enough to avoid HPG axis effects.
3. Functional endpoints are hard to hit. The FDA does not care if you gain 1 kg of lean mass. They care if you can climb stairs better, recover from surgery faster, or live longer. SARMs have consistently struggled with functional endpoints.
4. The risk-benefit math does not work for pharmaceutical companies. Developing a SARM costs hundreds of millions. The target populations (cachexia, osteoporosis, sarcopenia) already have treatment options. The incremental benefit of a SARM over existing therapies has not been compelling enough.
5. The gray market undercuts commercial viability. Why would a company invest in approval when people already buy the raw compound for $30 online?

What Users Should Actually Know

If you are considering SARMs or already using them, here is what the data actually supports:

• Suppression is not optional. Every SARM suppresses endogenous testosterone to some degree. "No PCT needed" is a myth at effective doses.
• Selectivity degrades with dose. At the low clinical doses (1-3mg Ostarine, 1mg LGD-4033), selectivity is reasonable. At the doses commonly used in fitness contexts (25mg+ Ostarine, 10mg+ LGD), you are well outside the studied range and selectivity assumptions break down.
• Product quality is a coin flip. Over-the-counter and online SARM products are frequently mislabeled, underdosed, overdosed, or contaminated. Without third-party testing of the specific batch you purchased, you do not actually know what you are taking.
• Bloodwork is mandatory, not optional. At minimum: comprehensive metabolic panel (liver function), lipid panel, total and free testosterone, LH, FSH before, during, and after any SARM cycle.
• The long-term data does not exist. The longest published SARM trial was 16 weeks. Nobody knows what 5 or 10 years of intermittent SARM use does to liver function, cardiovascular health, or cancer risk.

The Honest Assessment

SARMs are not useless. The clinical data for Ostarine and LGD-4033 shows real, measurable anabolic effects at low doses with a side effect profile that is genuinely milder than traditional anabolic steroids.

But they are not what the internet promised either. They are not side-effect-free. They are not "natural testosterone boosters." They are investigational drugs that failed to achieve regulatory approval, sold by unregulated vendors, used at unstudied doses, with no long-term safety data.

Treat them accordingly.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. SARMs are not approved by the FDA for human use and are prohibited by WADA and most athletic organizations. Products sold online as SARMs are frequently mislabeled or contaminated. The clinical data discussed is from investigational trials and does not establish safety or efficacy for consumer use. Consult a qualified healthcare professional before making decisions about your health. CompoundIQ Research assumes no liability for actions taken based on this content.